scPharmaceuticals Prices of $50 Million Public Offering

BURLINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 6,620,000 shares of its common stock at a public offering price of $5.25 per share and, to an investor in lieu of common stock, a prefunded warrant to purchase up to 2,905,000 shares of common stock at a purchase price of $5.249 per underlying share, for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses and excluding the exercise of the pre-funded warrant. The prefunded warrant has an exercise price of $0.001 per share.  All of the shares and the prefunded warrant are being offered by scPharmaceuticals. The offering is expected to close on November 25, 2022, subject to the satisfaction of customary closing conditions.

SVB Securities and Cowen are acting as joint book-running managers for the offering. H.C. Wainwright & Co. and Maxim Group LLC are acting as co-managers for the offering.